McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a March 31, 2014 edition of Law360.com in an article entitled, “Fed. Circ.’s Claim Construction Rule At Stake In Teva Case.” In taking Teva Pharmaceuticals USA Inc.’s appeal of a ruling invalidating patents covering its multiple sclerosis drug Copaxone, the U.S. Supreme Court could dramatically alter how the Federal Circuit reviews claim construction findings, experts say, with some expecting a decision that will lead to a more deferential standard of review — and fewer Federal Circuit appeals. View the article